Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
25.09
-0.03 (-0.12%)
At close: May 12, 2025, 4:00 PM
24.71
-0.38 (-1.51%)
After-hours: May 12, 2025, 6:36 PM EDT
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Pacira BioSciences stock have an average target of 29.89, with a low estimate of 10 and a high estimate of 65. The average target predicts an increase of 19.13% from the current stock price of 25.09.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Pacira BioSciences stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 3 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $32 → $30 | Strong Buy | Maintains | $32 → $30 | +19.57% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +27.54% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $65 | Strong Buy | Maintains | $48 → $65 | +159.07% | Apr 8, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $24 | Buy | Maintains | $17 → $24 | -4.34% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +27.54% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
767.42M
from 700.97M
Increased by 9.48%
Revenue Next Year
854.19M
from 767.42M
Increased by 11.31%
EPS This Year
2.96
from -2.15
EPS Next Year
3.72
from 2.96
Increased by 25.64%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 813.7M | 966.5M | 1.1B | ||
| Avg | 767.4M | 854.2M | 940.3M | ||
| Low | 725.2M | 769.8M | 798.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.1% | 25.9% | 27.0% | ||
| Avg | 9.5% | 11.3% | 10.1% | ||
| Low | 3.5% | 0.3% | -6.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.54 | 4.74 | 6.28 | ||
| Avg | 2.96 | 3.72 | 4.64 | ||
| Low | 2.47 | 2.73 | 3.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 60.2% | 68.8% | ||
| Avg | - | 25.6% | 24.9% | ||
| Low | - | -7.6% | -17.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.